PT - JOURNAL ARTICLE AU - Meade, William AU - Weber, Allison AU - Phan, Tin AU - Hampston, Emily AU - Resa, Laura Figueroa AU - Nagy, John AU - Kuang, Yang TI - High accuracy indicators of androgen suppression therapy failure for prostate cancer – a modeling study AID - 10.1101/2022.06.24.22276874 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.24.22276874 4099 - http://medrxiv.org/content/early/2022/06/27/2022.06.24.22276874.short 4100 - http://medrxiv.org/content/early/2022/06/27/2022.06.24.22276874.full AB - Prostate Cancer is a serious public health concern in the United States. The primary obstacle to effective long-term management for prostate cancer patients is the eventual development of treatment resistance. Due to the uniquely chaotic nature of the neoplastic genome, it is difficult to determine the evolution of tumor composition over the course of treatment. Hence, a drug is often applied continuously past the point of effectiveness, thereby losing any potential treatment combination with that drug permanently to resistance. If a clinician is aware of the timing of resistance to a particular drug, then they may have a crucial opportunity to adjust the treatment to retain the drug usefulness in potential treatment combination or strategy. In this study, we investigate new methods of predicting treatment failure due to treatment resistance using a novel mechanistic model built on an evolutionary interpretation of Droop cell quota theory. We analyze our proposed methods using patient PSA and androgen data from a clinical trial of intermittent treatment with androgen deprivation therapy. Our results produce two indicators of treatment failure. The first indicator is calculated using our mathematical model with a predictive accuracy of 87.3% (sensitivity: 96.1%, specificity: 65%). The second indicator is calculated directly from serum androgen and PSA data with a predictive accuracy of 88.7% (sensitivity: 90.2%, specificity: 85%). The high sensitivity of the first indicator and the high specificity of the second indicator means they can complement one another in clinical settings. Our results demonstrate the potential and feasibility of using evolutionary tumor dynamics models in combination with the appropriate data to aid in the adaptive management of prostate cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementW.M., A.W. and E.H. were supported partially by the Research Experience for Undergraduate program, (AM)∧2 REU, at Arizona State University. T.P. is supported by the director fellowship at Los Alamos National Laboratory. Y.K. is partially supported by the US National Science Foundation Rules of Life program DEB -1930728 and the NIH grant 5R01GM131405-02.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source of clinical data is available in Bruchovsky, Nicholas, Laurence Klotz, Juanita Crook, Shawn Malone, Charles Ludgate, W. James Morris, Martin E. Gleave, and S. Larry Goldenberg. "Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters." Cancer 107, no. 2 (2006): 389-395.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are available online at indicated in the data availability section of the study.